Capital Research Global Investors
ELVN icon

Capital Research Global Investors’s Enliven Therapeutics ELVN Stock Holding History

Capital Research Global Investors’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,304,346
Closed -$20.1M – 471
2025
Q4 		$20.1M Sell
1,304,346
-11,119
-0.8% -$222K ﹤0.01% 399
2025
Q3 		$26.9M Hold
1,315,465
– – 0.01% 391
2025
Q2 		$26.4M Buy
+1,315,465
New +$24.9M 0.01% 381

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Capital Research Global Investors's ELVN Position: Q1 2026 in Review

Capital Research Global Investors sold out of Enliven Therapeutics (ELVN) in Q1 2026, closing a stake of 1,304,346 shares — an estimated $20.1M sold.

Capital Research Global Investors first reported a position in ELVN in Q2 2025 and held it in 3 quarters. The position peaked at $26.9M in Q3 2025. 170 funds tracked by Wall St. Rank hold ELVN as of Q1 2026.

  • Capital Research Global Investors reported no remaining Enliven Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Capital Research Global Investors sold 1,304,346 Enliven Therapeutics shares in Q1 2026, an estimated $20.1M.
  • Capital Research Global Investors first reported a position in Enliven Therapeutics in Q2 2025 and held it in 3 quarters.
  • Capital Research Global Investors's Enliven Therapeutics position peaked at $26.9M in Q3 2025.
  • 170 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q1 2026.

Based on Capital Research Global Investors's 13F filing for Q1 2026, filed 13 May 2026.